NO20013860L - 16-hydroksyöstratriener som selektive östrogener - Google Patents

16-hydroksyöstratriener som selektive östrogener

Info

Publication number
NO20013860L
NO20013860L NO20013860A NO20013860A NO20013860L NO 20013860 L NO20013860 L NO 20013860L NO 20013860 A NO20013860 A NO 20013860A NO 20013860 A NO20013860 A NO 20013860A NO 20013860 L NO20013860 L NO 20013860L
Authority
NO
Norway
Prior art keywords
hydroxyestatrienes
selective estrogens
estrogens
selective
Prior art date
Application number
NO20013860A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013860D0 (no
Inventor
Hermann Kuenzer
Rudolf Knauthe
Monika Lessl
Karl-Heinrich Fritzemeier
Christa Hegele-Hartung
Ulf Boemer
Gerd Mueller
Dirk Kosemund
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20013860D0 publication Critical patent/NO20013860D0/no
Publication of NO20013860L publication Critical patent/NO20013860L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20013860A 1999-02-09 2001-08-08 16-hydroksyöstratriener som selektive östrogener NO20013860L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19906159A DE19906159A1 (de) 1999-02-09 1999-02-09 16-Hydroxyestratriene als selektiv wirksame Estrogene
PCT/EP2000/001073 WO2000047603A2 (de) 1999-02-09 2000-02-09 16-hydroxyestratriene als selektiv wirksame estrogene

Publications (2)

Publication Number Publication Date
NO20013860D0 NO20013860D0 (no) 2001-08-08
NO20013860L true NO20013860L (no) 2001-10-08

Family

ID=7897485

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013860A NO20013860L (no) 1999-02-09 2001-08-08 16-hydroksyöstratriener som selektive östrogener

Country Status (30)

Country Link
EP (2) EP1144431B1 (hu)
JP (1) JP2002536455A (hu)
KR (1) KR20010101822A (hu)
CN (1) CN1346364A (hu)
AR (1) AR034392A1 (hu)
AT (1) ATE313553T1 (hu)
AU (1) AU2909500A (hu)
BG (1) BG105804A (hu)
BR (1) BR0008076A (hu)
CA (1) CA2359660A1 (hu)
CO (1) CO5150223A1 (hu)
CZ (1) CZ20012843A3 (hu)
DE (2) DE19906159A1 (hu)
DK (1) DK1144431T3 (hu)
EA (1) EA200100828A1 (hu)
EE (1) EE200100412A (hu)
ES (1) ES2255983T3 (hu)
HK (1) HK1046145A1 (hu)
HU (1) HUP0200055A3 (hu)
IL (1) IL144455A0 (hu)
MX (1) MXPA01008065A (hu)
NO (1) NO20013860L (hu)
NZ (1) NZ513409A (hu)
PE (1) PE20001461A1 (hu)
PL (1) PL350360A1 (hu)
PT (1) PT1144431E (hu)
SK (1) SK11302001A3 (hu)
WO (1) WO2000047603A2 (hu)
YU (1) YU57201A (hu)
ZA (1) ZA200107388B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
DE10048634A1 (de) * 2000-09-27 2002-04-18 Jenapharm Gmbh 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring
EP1365768B1 (en) * 2001-02-27 2008-05-07 Bayer Schering Pharma Aktiengesellschaft Use of er-beta selective antagonists as contraceptives
DE10151365A1 (de) 2001-10-17 2003-04-30 Schering Ag 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten
DE10151114A1 (de) * 2001-10-15 2003-04-17 Schering Ag 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate
DE10151363A1 (de) * 2001-10-17 2003-05-08 Schering Ag Somatotrope Therapie
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
SE536263C2 (sv) * 2011-12-21 2013-07-23 Airqone Building Scandinavia Ab Reningsanordning för gasmedium innefattande medel för kontrollerad tillförsel av joniserad luft
US20200377546A1 (en) * 2016-08-22 2020-12-03 Or-Genix Therapeutics, Inc. Estrogen receptor beta selective ligands
WO2019041078A1 (en) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
US11512107B2 (en) 2018-09-07 2022-11-29 Trustees Of Dartmouth College Methods for assembly of tetracyclic compounds by stereoselective C9-C10 bond formation
WO2020051329A1 (en) * 2018-09-07 2020-03-12 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof
CN115154474A (zh) * 2021-04-01 2022-10-11 中国人民解放军总医院 一种环菠萝蜜烷型三萜皂苷化合物在制备t细胞免疫抑制剂中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079408A (en) * 1963-02-26 Ig-bisoxygenated iy-haloestra-
US3103524A (en) * 1963-09-10 Ratetraene-
GB823955A (en) * 1955-09-01 1959-11-18 Nepera Chemical Co Inc Improvements in steroid compounds and method for manufacture of same
GB804789A (en) * 1956-02-06 1958-11-26 Searle & Co 16-alkylestratriene-3,16,17-triols and derivatives thereof
US2779773A (en) * 1956-05-23 1957-01-29 Nepera Chemical Co Inc Steroid 3, 16alpha-diols and process
US3166473A (en) * 1962-04-12 1965-01-19 Mochida Pharm Co Ltd New esters of 1, 3, 5-estratriene-3, 16, 17-triol and novel pharmaceutical compositions containing new esters of 1, 3, 5-estratriene-3, 16, 17-triol and esters of 1, 3, 5-estratriene-3, 16, 17-triol
NL124324C (hu) * 1964-01-24
FR4339M (hu) * 1965-03-29 1966-08-08
FR5099M (hu) * 1966-01-12 1967-05-22
US3449383A (en) * 1967-02-16 1969-06-10 Searle & Co 17-oxygenated estra-1,3,5(10)-triene-3,11beta,16-triols,ethers and esters thereof
US3470159A (en) * 1967-07-13 1969-09-30 American Home Prod Estra-1,3,5(10),7-tetraenes and process of preparation
US3600705A (en) * 1969-02-27 1971-08-17 Gen Electric Highly efficient subcritically doped electron-transfer effect devices
CH538460A (de) * 1969-02-27 1973-06-30 Ciba Geigy Ag Verfahren zur Herstellung eines neuen hochwirksamen Östratriols
CH537915A (de) * 1969-02-27 1973-06-15 Ciba Geigy Ag Verfahren zur Herstellung eines neuen Östratriols
FR2034569B1 (hu) * 1969-02-27 1973-07-13 Ciba Geigy Ag
GB1235642A (en) * 1969-02-27 1971-06-16 Ciba Geigy A new oestratriol and a process for its manufacture
US3622670A (en) * 1969-08-22 1971-11-23 American Home Prod Method of inducing ovulation
IL38806A0 (en) * 1971-03-05 1972-04-27 Ciba Geigy Ag Pharmaceutical compositions comprising estrogens and anthracene derivatives
US3766224A (en) * 1971-06-03 1973-10-16 Sandoz Ag 15-methyl-substituted steroids
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
JPS5265259A (en) * 1975-11-27 1977-05-30 Takeda Chem Ind Ltd Synthesis of 16beta-alkylestradiol or its 17-esters
NL7613248A (nl) * 1976-11-26 1978-05-30 Akzo Nv Werkwijze voor het bereiden van nieuwe steroid- esters.
DD145919B1 (de) * 1978-06-28 1982-06-30 Kurt Ponsold Verfahren zur herstellung von 14,1 -methylenderivaten der oestranreihe
SE8305596D0 (sv) * 1983-10-12 1983-10-12 Leo Ab A selective acylation method
DE3510555A1 (de) * 1985-03-21 1986-09-25 Schering AG, 1000 Berlin und 4709 Bergkamen Estriolester
US4705783A (en) * 1985-06-25 1987-11-10 Sri International 9α, 11β-substituted and 11β-substituted estranes
HU208150B (en) * 1988-10-31 1993-08-30 Endorecherche Inc Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
SU1761760A1 (ru) * 1990-07-02 1992-09-15 Всесоюзный Эндокринологический Научный Центр Амн Ссср Способ получени 11-нитратов 9 @ , 11 @ -диоксистероидов
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung
DE4322186A1 (de) * 1993-07-03 1995-01-12 Jenapharm Gmbh Oral estrogen wirksame Ester des 14alpha, 15alpha-Methylen-estradiols
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
SE9502921D0 (sv) * 1995-08-23 1995-08-23 Astra Ab New compounds
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19815060A1 (de) * 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie

Also Published As

Publication number Publication date
AU2909500A (en) 2000-08-29
ES2255983T3 (es) 2006-07-16
SK11302001A3 (sk) 2002-01-07
EE200100412A (et) 2002-12-16
AR034392A1 (es) 2004-02-25
WO2000047603A9 (de) 2001-09-07
NZ513409A (en) 2004-02-27
DK1144431T3 (da) 2006-05-08
CO5150223A1 (es) 2002-04-29
EP1580192A2 (de) 2005-09-28
WO2000047603A2 (de) 2000-08-17
BR0008076A (pt) 2002-02-05
BG105804A (en) 2002-03-29
CA2359660A1 (en) 2000-08-17
NO20013860D0 (no) 2001-08-08
KR20010101822A (ko) 2001-11-14
ATE313553T1 (de) 2006-01-15
DE50011908D1 (de) 2006-01-26
EA200100828A1 (ru) 2002-04-25
HK1046145A1 (zh) 2002-12-27
PL350360A1 (en) 2002-12-02
CZ20012843A3 (cs) 2002-01-16
EP1144431A2 (de) 2001-10-17
ZA200107388B (en) 2005-01-25
CN1346364A (zh) 2002-04-24
EP1144431A3 (de) 2002-06-12
YU57201A (sh) 2005-06-10
WO2000047603A3 (de) 2001-08-02
HUP0200055A3 (en) 2002-10-28
JP2002536455A (ja) 2002-10-29
IL144455A0 (en) 2002-05-23
PT1144431E (pt) 2006-05-31
DE19906159A1 (de) 2000-08-10
PE20001461A1 (es) 2000-12-18
HUP0200055A2 (hu) 2002-05-29
EP1144431B1 (de) 2005-12-21
MXPA01008065A (es) 2002-04-24

Similar Documents

Publication Publication Date Title
NO2019016I1 (no) dasatinib
LU92057I2 (fr) Vandétanib (CAPRELSA)
DE50007817D1 (de) Mikrospiegel
TR200000520A3 (tr) 4-Fenil-piridin türevleri.
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
DK1147121T3 (da) Ketolidantibiotika
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
NO20013860D0 (no) 16-hydroksyostratriener som selektive ostrogener
DE50000805D1 (de) Aufsitzspanner
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50003259D1 (de) Textilie
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE10082008D2 (de) Ausbeulgerät
ATE269311T1 (de) Benzoylpyridazine
DK1380585T3 (da) Pyrazolopyridinon som mellemprodukt
DE50003283D1 (de) Exzenterspannzwinge
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter
DE50002156D1 (de) Azofarbstoffmischungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application